Anti-cancer drugs

Keyphrases

Publications

volume 35, number 6, 2024

Valeria Cognigni, Giulia Claire Giudice, Francesca Bozzetti, Gianluca Milanese, Ilaria Moschini, Miriam Casali, Giulia Mazzaschi, Marcello Tiseo
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer. Anti-cancer drugs 35 (6) (2024)
Shuping Yang, Zhi Li, Jiamei Yi, Mingyue Pan, Weiling Cao, Jing Ma, Peng Zhang
Nebivolol, an antihypertensive agent, has new application in inhibiting melanoma. Anti-cancer drugs 35 (6) (2024)
Valeria Cognigni, Giulia Claire Giudice, Francesca Bozzetti, Gianluca Milanese, Ilaria Moschini, Miriam Casali, Giulia Mazzaschi, Marcello Tiseo
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer. Anti-cancer drugs 35 (6) (2024)
Shuping Yang, Zhi Li, Jiamei Yi, Mingyue Pan, Weiling Cao, Jing Ma, Peng Zhang
Nebivolol, an antihypertensive agent, has new application in inhibiting melanoma. Anti-cancer drugs 35 (6) (2024)
Juanjuan Liu, Hongtao Lei, Ding Zhang, Ning Zhang
Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review. Anti-cancer drugs 35 (6) (2024)
Valeria Cognigni, Giulia Claire Giudice, Francesca Bozzetti, Gianluca Milanese, Ilaria Moschini, Miriam Casali, Giulia Mazzaschi, Marcello Tiseo
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer. Anti-cancer drugs 35 (6) (2024)
Andrea Luciani, Lorenzo Dottorini, Elena Battaiotto, Fausto Petrelli
Network meta-analysis of first-line systemic regimens for older patients with advanced NSCLC. Anti-cancer drugs 35 (6) (2024)
Andrea Luciani, Lorenzo Dottorini, Elena Battaiotto, Fausto Petrelli
Network meta-analysis of first-line systemic regimens for older patients with advanced NSCLC. Anti-cancer drugs 35 (6) (2024)
Zhanwen Xu, Haiyan Jia, Xiaoping Yin
Delayed cardiotoxicity following osimertinib therapy in non-small cell lung cancer: a unique case report. Anti-cancer drugs 35 (6) (2024)
Juanjuan Liu, Hongtao Lei, Ding Zhang, Ning Zhang
Brigatinib combined with cetuximab in the fifth-line treatment of non-small cell lung cancer with EGFR p.C797S mutation in critically ill patients: a report of two cases and literature review. Anti-cancer drugs 35 (6) (2024)
Shuping Yang, Zhi Li, Jiamei Yi, Mingyue Pan, Weiling Cao, Jing Ma, Peng Zhang
Nebivolol, an antihypertensive agent, has new application in inhibiting melanoma. Anti-cancer drugs 35 (6) (2024)
Chong Zhao, Fang Zhang, Yang Tian, Bingjie Tang, Jing Luo, Jianhui Zhang
m 6 A reader IGF2BP1 reduces the sensitivity of nasopharyngeal carcinoma cells to Taxol by upregulation of AKT2. Anti-cancer drugs 35 (6) (2024)

volume 35, number 7, 2024

Yan Wang, Liang Gao, Feiyu Wang, Cunjun Yu, Chen Chen, Chunwei Xia
GPRC5A promotes paclitaxel resistance and glucose content in NSCLC. Anti-cancer drugs 35 (7) (2024)
Adam Barsouk, Omar Elghawy, Sara Stone, Aditi Singh
Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition. Anti-cancer drugs 35 (7) (2024)
Sena Valcárcel, Noemi Villanueva, Carlos Álvarez, Emilio Esteban
EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report. Anti-cancer drugs 35 (7) (2024)
Fan-Jie Qu, Yan Kong, Xin Yan, Hai Wang
Elderly patients with advanced HER2-positive breast cancer with liver metastases benefit from low dose disitamab vedotin (RC48): case series and literature review. Anti-cancer drugs 35 (7) (2024)
Fan-Jie Qu, Yan Kong, Xin Yan, Hai Wang
Elderly patients with advanced HER2-positive breast cancer with liver metastases benefit from low dose disitamab vedotin (RC48): case series and literature review. Anti-cancer drugs 35 (7) (2024)
Feng Ke, Nan Wang, Xuan Zhang, Rui Liu, Tingting Ren, Jing Ke, Jianye Yang, Haihan Yan, Jianmin Ma
Enhancement of vincristine sensitivity in retinoblastoma through Janus kinase inhibition by ruxolitinib. Anti-cancer drugs 35 (7) (2024)
Dan Yang, Xiaomin Li, Xiaoying Xue, Leilei Jiang, Anhui Shi, Jun Zhao
Anlotinib hydrochloride consolidation after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: a truncated, randomized, multicenter, clinical study (ALTER-L029). Anti-cancer drugs 35 (7) (2024)
Marion Ferreira, Matthew I Ebia, Karen L Reckamp
Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancer. Anti-cancer drugs 35 (7) (2024)
Timothy J Liu, Erin K McMeniman
Pityriasiform drug eruption associated with venetoclax for acute myeloid leukaemia. Anti-cancer drugs 35 (7) (2024)
Marion Ferreira, Matthew I Ebia, Karen L Reckamp
Early dose reduction of osimertinib in advanced EGFR -mutated non-small cell lung cancer. Anti-cancer drugs 35 (7) (2024)
Mingtao Shi, Yongchun Zhang
Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review. Anti-cancer drugs 35 (7) (2024)
Ping Yang, Tao Pan, Ming-Kun Wang, Meng-Sheng Xiao, Shuang Zhang, Sha Liu
Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma. Anti-cancer drugs 35 (7) (2024)
Run Shi, Ruixue Yu, Fei Lian, Yalong Zheng, Shunhang Feng, Changzhi Li, Xinhua Zheng
Targeting HSP47 for cancer treatment. Anti-cancer drugs 35 (7) (2024)
Sena Valcárcel, Noemi Villanueva, Carlos Álvarez, Emilio Esteban
EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report. Anti-cancer drugs 35 (7) (2024)
Run Shi, Ruixue Yu, Fei Lian, Yalong Zheng, Shunhang Feng, Changzhi Li, Xinhua Zheng
Targeting HSP47 for cancer treatment. Anti-cancer drugs 35 (7) (2024)
Shuling Zhang, Lanxia Zhou, Jincai Yang, Jianle Lu, Lili Tao, Youfan Feng, Juan Cheng, Li Zhao
Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTOR. Anti-cancer drugs 35 (7) (2024)
Adam Barsouk, Omar Elghawy, Sara Stone, Aditi Singh
Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition. Anti-cancer drugs 35 (7) (2024)
Yan Wang, Liang Gao, Feiyu Wang, Cunjun Yu, Chen Chen, Chunwei Xia
GPRC5A promotes paclitaxel resistance and glucose content in NSCLC. Anti-cancer drugs 35 (7) (2024)
Shuling Zhang, Lanxia Zhou, Jincai Yang, Jianle Lu, Lili Tao, Youfan Feng, Juan Cheng, Li Zhao
Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTOR. Anti-cancer drugs 35 (7) (2024)

volume 35, number 8, 2024

Xiang Yong, Yanling Zhang, Heng Tang, Huaiyuan Hu, Rui Song, Qiang Wu
CDKN2A inhibited ferroptosis through activating JAK2/STAT3 pathway to modulate cisplatin resistance in cervical squamous cell carcinoma. Anti-cancer drugs 35 (8) (2024)
Lili Cai, Lan Qu, Yanjie Cheng, Jinfeng Zhang, Shiying Li, Shenghong Wu
Study on the therapeutic effect of sintilimab combined with modified DCF regimen on advanced gastric cancer and its impact on Th1/Th2 immune balance. Anti-cancer drugs 35 (8) (2024)
Lili Cai, Lan Qu, Yanjie Cheng, Jinfeng Zhang, Shiying Li, Shenghong Wu
Study on the therapeutic effect of sintilimab combined with modified DCF regimen on advanced gastric cancer and its impact on Th1/Th2 immune balance. Anti-cancer drugs 35 (8) (2024)
Linger Liu, Baisong Chen, Mengyao Tang, Yinhong Guo, Jili Hou, Wu Zhou, Xiaolian Zhu
Combination of anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report. Anti-cancer drugs 35 (8) (2024)
Bin Liu, Ying Peng, Yanjun Su, Chang Diao, Jun Qian, Xiangxiang Zhan, Ruochuan Cheng
Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer. Anti-cancer drugs 35 (8) (2024)
Fei Cai, Yuanyuan Zhao, Shuxi Song, Dong Zhao, Zhendong Zheng, Long Xu
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report. Anti-cancer drugs 35 (8) (2024)
Ali Kaan Güren, Erkam Kocaaslan, Yeşim Ağyol, Nargiz Majidova, Nadiye Sever, Pinar Erel, Abdussamet Çelebi, Rukiye Arikan, Selver Işik, Murat Sari, İbrahim Vedat Bayoğlu, Osman Köstek
HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report. Anti-cancer drugs 35 (8) (2024)
Xiaofu Wu, Wenyuan Zhang
TRIM11 expression levels was downregulated and prevents ferroptosis of cardiomyocyte by Dusp6 in acute myocardial infarction. Anti-cancer drugs 35 (8) (2024)
Tao Luan, Xinqing Lin, Xiaohong Xie, Gang Yang, Shuaiying Wang, Jianqing Hao, Chengzhi Zhou
First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anti-cancer drugs 35 (8) (2024)
Marie-Eve Roy, Carolane Veilleux, Alexis Paquin, Alexandre Gagnon, Borhane Annabi
Transcriptional regulation of CYR61 and CTGF by LM98: a synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic mimicry in glioblastoma cells. Anti-cancer drugs 35 (8) (2024)
Lili Cai, Lan Qu, Yanjie Cheng, Jinfeng Zhang, Shiying Li, Shenghong Wu
Study on the therapeutic effect of sintilimab combined with modified DCF regimen on advanced gastric cancer and its impact on Th1/Th2 immune balance. Anti-cancer drugs 35 (8) (2024)
Shweta Gulia, Prakash Chandra, Asmita Das
Combating anoikis resistance: bioactive compounds transforming prostate cancer therapy. Anti-cancer drugs 35 (8) (2024)
Zhenyu Li, Xiangji Lu, Jing Zhang, Tao Liu, Mingzhi Xu, Shuai Liu, Junguo Liang
KAT8 enhances the resistance of lung cancer cells to cisplatin by acetylation of PKM2. Anti-cancer drugs 35 (8) (2024)
Zhenyu Li, Xiangji Lu, Jing Zhang, Tao Liu, Mingzhi Xu, Shuai Liu, Junguo Liang
KAT8 enhances the resistance of lung cancer cells to cisplatin by acetylation of PKM2. Anti-cancer drugs 35 (8) (2024)
Tao Luan, Xinqing Lin, Xiaohong Xie, Gang Yang, Shuaiying Wang, Jianqing Hao, Chengzhi Zhou
First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anti-cancer drugs 35 (8) (2024)
Monica Pluchino, Irene Testi, Roberta Minari, Alessandra Dodi, Giulia Airò, Giulia Mazzaschi, Michela Verzè, Alessia Adorni, Letizia Gnetti, Cinzia Azzoni, Costanza Anna Maria Lagrasta, Federica Pecci, Marcello Tiseo
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient. Anti-cancer drugs 35 (8) (2024)
Marie-Eve Roy, Carolane Veilleux, Alexis Paquin, Alexandre Gagnon, Borhane Annabi
Transcriptional regulation of CYR61 and CTGF by LM98: a synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic mimicry in glioblastoma cells. Anti-cancer drugs 35 (8) (2024)
Xiaojing Tie, Hang Li, Ling Gao, Peijie Liu, Yaohong Gao, Mingxin Jin, Guangting Duan, Zhenying Yi
Enhancing the management of locally advanced head and neck malignancies and cases with local/neck recurrence and metastasis through the integration of anlotinib with concurrent radiochemotherapy. Anti-cancer drugs 35 (8) (2024)
Linger Liu, Baisong Chen, Mengyao Tang, Yinhong Guo, Jili Hou, Wu Zhou, Xiaolian Zhu
Combination of anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report. Anti-cancer drugs 35 (8) (2024)